首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project
【24h】

Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project

机译:德国继发转移切除术对大肠癌的姑息治疗-多学科治疗方法对预后和费用的影响:北巴伐利亚IVOPAK I项目

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: The aim of this study was to evaluate the quality of care and interdisciplinary cooperation in the palliative treatment of colorectal cancer (CRC), including the associated costs. Patients and Methods: 103 patients were enrolled from 13 institutions to reflect the existing clinical treatment reality and costs of palliative CRC treatment. We present the clinical outcome of the patients and compare the results obtained in the 3 centers with double-figure recruitment numbers (centers A, B, and C). Results: First-line treatment with 5-fluorouracil monotherapy was applied in exceptional cases. The regular treatment method comprised either an irinotecan- (30%) or an oxaliplatin-based regimen (32%). Biological agents were added to the treatment of 33 patients (32%). The median overall survival (OS) of the total patient collective was 25 months. The OS differed significantly in 2 out of the 3 centers, ranging between 27 and 11 months. Secondary metastasis resections were performed in 26% of the total patient collective. The center with the most favorable outcome results also had the lowest costs for palliative treatment and care, including the lowest drug costs. Conclusion: A combined chemotherapy treatment was the rule. Concerning biological agents, a significant lack of their application in first-line treatment and the quality of interdisciplinary cooperation have to be addressed. (C) 2014 S. Karger AG, Basel
机译:目的:本研究的目的是评估姑息治疗结直肠癌(CRC)的护理质量和跨学科合作的质量,包括相关费用。患者与方法:来自13个机构的103例患者反映了现有的临床治疗现实和姑息CRC治疗的费用。我们介绍了患者的临床结果,并比较了在三个中心有双位数招聘人数(中心A,B和C)获得的结果。结果:在特殊情况下,采用5-氟尿嘧啶单药一线治疗。常规治疗方法包括伊立替康(30%)或奥沙利铂(32%)治疗。添加了生物制剂治疗33例患者(32%)。全部患者集体的中位总生存期(OS)为25个月。 3个中心中有2个的OS显着不同,介于27到11个月之间。占总患者总数的26%进行了二次转移切除。结果效果最佳的中心也具有最低的姑息治疗和护理费用,包括最低的药物费用。结论:联合化疗是常规。关于生物制剂,必须解决其在一线治疗中的应用严重缺乏和跨学科合作的质量问题。 (C)2014 S.Karger AG,巴塞尔

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号